Table 5.
Summary of some of the topics discussed.
| GATHER1 | DERBY/OAKS | CHROMA/SPECTRI | SEATTLE | GATE | |
|---|---|---|---|---|---|
| Metric of PE | mm/year | mm2/year | mm2/year | mm2/year | mm2/year |
| Adjusted PE | No | Yes | Yes | Yes | No |
| Atrophy location | Extrafoveal | Any | Any | Any | Any |
| Intention to treat | Yes | Yes | Yes | Yes | No? |
| Discontinuation, % | 20.1 | 11.4 | 7.9 | 37.0 | 29.9 |
| Specific adverse events | eAMD | eAMD | Increased IOP | Delayed DA | Reduced VA |
DA: dark adaptation; eAMD: exudative age-related macular degeneration; IOP: intraocular pressure; PE: primary endpoint; VA: best-corrected visual acuity.